Our results demonstrate that the brain-penetrating ALS drug edaravone promotes RET expression and GDNF release in MNs, which mechanism likely mediates the neuroprotective effect of edaravone on miMNs. The gene discussed is GDNF; the disease is amyotrophic lateral sclerosis.